Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The signaling mechanisms between prostate cancer cells and infiltrating immune cells may illuminate novel therapeutic approaches. Here, utilizing a prostate adenocarcinoma model driven by loss of Pten and Smad4, we identify polymorphonuclear myeloid-derived suppressor cells (MDSC) as the major infiltrating immune cell type, and depletion of MDSCs blocks progression. Employing a novel dual reporter prostate cancer model, epithelial and stromal transcriptomic profiling identified CXCL5 as a cancer-secreted chemokine to attract CXCR2-expressing MDSCs, and, correspondingly, pharmacologic inhibition of CXCR2 impeded tumor progression. Integrated analyses identified hyperactivated Hippo–YAP signaling in driving CXCL5 upregulation in cancer cells through the YAP–TEAD complex and promoting MDSC recruitment. Clinicopathologic studies reveal upregulation and activation of YAP1 in a subset of human prostate tumors, and the YAP1 signature is enriched in primary prostate tumor samples with stronger expression of MDSC-relevant genes. Together, YAP-driven MDSC recruitment via heterotypic CXCL5–CXCR2 signaling reveals an effective therapeutic strategy for advanced prostate cancer. Significance: We demonstrate a critical role of MDSCs in prostate tumor progression and discover a cancer cell nonautonomous function of the Hippo–YAP pathway in regulation of CXCL5, a ligand for CXCR2-expressing MDSCs. Pharmacologic elimination of MDSCs or blocking the heterotypic CXCL5–CXCR2 signaling circuit elicits robust antitumor responses and prolongs survival. Cancer Discov; 6(1); 80–95. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“MDSCs are of myeloid cell lineage, and their coordinated regulation represents one of the most complex aspects of cancer–host interactions (37).”
A global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491 · cited 1×
“The mTmG allele (22) allows Cre-dependent GFP expression in prostate epithelial cells and ubiquitous tdTomato expression in all other non–Creexpressing cells (Fig.”
Self-citationInfluence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationCrucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993 · cited 1×
“Homozygous deletion of Pten in murine prostate elicited a strong senescence response that restricts tumor progression (33); thus, Pten-deficient prostate tumors are largely indolent and progress slowly to invasive prostate adenocarcinoma without metastasis to distant organs (11, 33).”
Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA
Liu, F., Song, Y. K., & Liu, D. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300947 · Cited by 1,727
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
Battaglia, M., Stabilini, A., & Roncarolo, M.-G. (2005) · Blood · doi:10.1182/blood-2004-10-3932 · Cited by 1,134
Schmielau, J., & Finn, O. J. (2001) · PubMed · Cited by 1,010
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918 · cited 2×
“To validate the CXCL5–CXCR2 axis in the recruitment of MDSCs to the TME of Ptenpc−/−Smad4pc−/− tumors, we assessed the impact of pharmacologic inhibition of CXCL5 and CXCR2 in MDSCs using a transwell migration assay (23).”
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment
Johnson, R., & Halder, G. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4161 · Cited by 881
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis
Zhao, B., Li, L., Wang, L., Wang, C.-Y., Yu, J., & Guan, K.-L. (2012) · Genes & Development · doi:10.1101/gad.173435.111 · Cited by 793
Self-citationKRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 3×
“Chromatin Immunoprecipitation ChIP was performed as described (26) using YAP1 antibody from Novus.”
Self-citationSMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
Ding, Z., Wu, C.-J., Chu, G. C., Xiao, Y., Ho, D., Zhang, J., Perry, S. R., Labrot, E. S., Wu, X., Lis, R., et al. (2011) · Nature · doi:10.1038/nature09677 · Cited by 515
Self-citationWallace, T. A., Prueitt, R. L., Yi, M., Howe, T. M., Gillespie, J. W., Yfantis, H. G., Stephens, R. M., Caporaso, N. E., Loffredo, C. A., & Ambs, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2608 · Cited by 511
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., et al. (2014) · Nature · doi:10.1038/nature13638 · Cited by 388 · cited 2×
“MDSCs have been identified recently as a TME constituent in an indolent prostate cancer mouse model with conditional Pten deletion (9) and demonstrated to antagonize senescence during early tumorigenesis (10).”
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 386
Toh, B., Wang, X., Keeble, J., Sim, W. J., Khoo, K., Wong, W.-C., Kato, M., Prevost-Blondel, A., Thiery, J.-P., & Abastado, J.-P. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001162 · Cited by 369
Inhibition of tumor growth by elimination of granulocytes.
Pekarek, L. A., Starr, B. A., Toledano, A. Y., & Schreiber, H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.435 · Cited by 340
Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
Stromnes, I. M., Brockenbrough, J. S., Izeradjene, K., Carlson, M. A., Cuevas, C., Simmons, R. M., Greenberg, P. D., & Hingorani, S. R. (2014) · Gut · doi:10.1136/gutjnl-2013-306271 · Cited by 331
Kwon, A. T., Arenillas, D. J., Hunt, R. W., & Wasserman, W. W. (2012) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.112.003202 · Cited by 282
Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer
Vuk‐Pavlović, S., Bulur, P. A., Lin, Y., Qin, R., Szumlanski, C. L., Zhao, X., & Dietz, A. B. (2010) · The Prostate · doi:10.1002/pros.21078 · Cited by 266
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
Filipazzi, P., Huber, V., & Rivoltini, L. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1161-9 · Cited by 243
Qin, H., Lerman, B., Sakamaki, I., Wei, G., Cha, S. C., Rao, S. S., Qian, J., Hailemichael, Y., Nurieva, R., Dwyer, K. C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3560 · Cited by 233
Single-cell mass cytometry for analysis of immune system functional states
Bjornson, Z. B., Nolan, G. P., & Fantl, W. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.07.004 · Cited by 224
Ding, Z., Wu, C.-J., Jaskelioff, M., Ivanova, E., Kost-Alimova, M., Protopopov, A., Chu, G. C., Wang, G., Lu, X., Labrot, E. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.039 · Cited by 220 · cited 1×
“Finally, to test if targeting YAP1 in vivo can impair the infiltration of MDSCs and inhibit tumor growth, we used our recently isolated syngeneic murine prostate cancer line PPS, which is derived from the backcrossed Ptenpc−/−Smad4pc−/−Trp53pc−/− model (31) and can form subcutaneous or orthotopic tumors robustly in C5…”
Self-citationIdorn, M., Køllgaard, T., Kongsted, P., Sengeløv, L., & thor Straten, P. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1591-2 · Cited by 184
Lunardi, A., Ala, U., Epping, M. T., Salmena, L., Clohessy, J. G., Webster, K. A., Wang, G., Mazzucchelli, R., Bianconi, M., Stack, E. C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2650 · Cited by 144
Self-citationGarcia, A. J., Ruscetti, M., Arenzana, T. L., Tran, L. M., Bianci-Frias, D., Sybert, E., Priceman, S. J., Wu, L., Nelson, P. S., Smale, S. T., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00090-14 · Cited by 142
Wang, G., Lunardi, A., Zhang, J., Chen, Z., Ala, U., Webster, K. A., Tay, Y., Gonzalez-Billalabeitia, E., Egia, A., Shaffer, D. R., et al. (2013) · Nature Genetics · doi:10.1038/ng.2654 · Cited by 137
Self-citationTherapeutic targeting of the prostate cancer microenvironment
Κάρλου, Μ., Tzelepi, V., & Efstathiou, E. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.134 · Cited by 131
Bierie, B., Stover, D. G., Abel, T. W., Chytil, A., Gorska, A. E., Aakre, M., Forrester, E., Yang, L., Wagner, K.-U., & Moses, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5597 · Cited by 124
Nguyen, L. T., Tretiakova, M. S., Silvis, M. R., Lucas, J., Klezovitch, O., Coleman, I., Bolouri, H., Kutyavin, V. I., Morrissey, C., True, L. D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.005 · Cited by 123
Liu, Q., Russell, M. R., Shahriari, K. S., Jernigan, D. L., Lioni, M., Garcia, F. U., & Fatatis, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3970 · Cited by 111
Szuster‐Ciesielska, A., Hryciuk-Umer, E., Stepulak, A., Kupisz, K., & Kandefer‐Szerszeń, M. (2004) · Acta Oncologica · doi:10.1080/02841860410029708 · Cited by 80
Brusa, D., Simone, M., Gontero, P., Spadi, R., Racca, P., Micari, J., Degiuli, M., Carletto, S., Tizzani, A., & Matera, L. (2013) · International Journal of Urology · doi:10.1111/iju.12086 · Cited by 66
Cited by
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
The Hippo Pathway: Biology and Pathophysiology
Ma, S., Meng, Z., Chen, R., & Guan, K.-L. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111829 · Cited by 1,387
Lv, M., Chen, M., Zhang, R., Zhang, W., Wang, C., Zhang, Y., Wei, X., Guan, Y., Liu, J., Feng, K., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00395-4 · Cited by 1,040
Metadata
- Authors
- Wang, G., Lu, X., Dey, P., Deng, P., Wu, C. C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., Zhang, J., Li-Ning-Tapia, E. M., Kapoor, A., Wu, C.-J., Patel, N. B., Guo, Z., Ramamoorthy, V., Tieu, T. N., Heffernan, T., Zhao, D., Shang, X., Khadka, S., Hou, P., Hu, B., Jin, E.-J., Yao, W., Pan, X., Ding, Z., Shi, Y., Li, L., Chang, Q., Troncoso, P., Logothetis, C. J., McArthur, M. J., Chin, L., Wang, Y. A., & DePinho, R. A.
- Venue
- Cancer Discovery
- Published
- 2016-01-01
- Volume
- 6
- Issue
- 1
- Pages
- 80-95
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2206971126
- Cited by
- 553
- References
- 41
- FWCI
- 11.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.